查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1463782

全球流感诊断市场：市场规模和份额分析（按产品、测试类型和最终用户）、行业需求预测（截至 2030 年）

Influenza Diagnostics Market Size and Share Analysis by Product, Test Type, End User - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 240 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场概况

预计全球流感诊断产业规模将在 2023 年达到 9.469 亿美元，并在 2030 年快速成长至 16.031 亿美元，预测期内复合年增长率为 7.9%。

由于流感加剧的慢性疾病增加、人口老化以及政府加强追踪疾病传播的力度，预计对流感分析解决方案的需求将激增。 技术复杂的感染诊断工具的成长也是该行业的主要驱动力。

关键见解

2023年，检测试剂盒和试剂品类占60%的市占率。

这是因为这些疾病现在更常见，人们对早期诊断的关注显着增加。

2023年，传统品类以40%的份额引领业界。

此类别的快速诊断流感测试由于其易于使用且快速得出结果而产生了最高的收入。

由于广泛的政府监管、顶尖公司的存在以及技术的进步，2023 年北美将占据 65% 的销售份额。

欧盟 (EU) 人口老化，到 2021 年，超过五分之一的人口年龄在 65 岁或以上，预计将占人口的相当大比例。

本报告分析了全球流感诊断市场，包括市场的基本结构和最新情况、主要促进和抑制因素以及全球、按地区和主要国家的市场规模前景（以货币形式计算） ，（2017-2030） ，按产品、检验类型和最终用户划分的详细趋势、当前市场竞争状况以及主要公司概况。

目录

第1章研究范围

第2章研究方法

第 3 章执行摘要

第 4 章市场指标

第5章产业展望

  • 市场动态
    • 趋势
    • 促进因素
    • 抑制因素/挑战
    • 促进/抑制因子影响分析
  • 新型冠状病毒感染 (COVID-19) 的影响
  • 波特五力分析

第6章世界市场

  • 摘要
  • 市场收入：依产品分类（2017-2030 年）
  • 市场收入：依测试类型划分（2017-2030 年）
    • 按类型划分的传统诊断测试市场收入（2017-2030 年）
    • 分子诊断测试市场收入：按类型划分（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）
  • 市场收入：按地区划分（2017-2030 年）

第7章北美市场

  • 摘要
  • 市场收入：依产品分类（2017-2030 年）
  • 市场收入：依测试类型划分（2017-2030 年）
    • 按类型划分的传统诊断测试市场收入（2017-2030 年）
    • 分子诊断测试市场收入：按类型划分（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）
  • 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第11章中东及非洲市场

第12章美国市场

  • 摘要
  • 市场收入：依产品分类（2017-2030 年）
  • 市场收入：依测试类型划分（2017-2030 年）
    • 按类型划分的传统诊断测试市场收入（2017-2030 年）
    • 分子诊断测试市场收入：按类型划分（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）

第13章加拿大市场

第14章德国市场

第15章法国市场

第16章英国市场

第17章义大利市场

第18章西班牙市场

第19章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

  • 市场参与者及其提供的产品/服务的列表
  • 主要公司的竞争基准
  • 各大公司的产品基准
  • 近期策略发展状况

第30章公司简介

  • 3M Company
  • Abbott Laboratories Inc.
  • Becton, Dickinson and Company
  • Meridian Bioscience Inc.
  • QuidelOrtho Corporation
  • F. Hoffmann-La Roche Ltd.
  • SA Scientific Ltd.
  • Sekisui Diagnostics LLC
  • Thermo Fisher Scientific Inc.
  • Hologic Inc.

第31章 附录

简介目录
Product Code: 12822

Market Overview

The worldwide influenza diagnostics industry generated USD 946.9 million in 2023, which is projected to surge to USD 1,603.1 million by 2030, experiencing a 7.9% CAGR during the projection period.

The requirement for influenza analysis solutions is estimated to surge as a outcome of the growing occurrence of chronic illnesses, several of which are deteriorated by the flu; rising aged populace, and growing government initiatives to track the spread of this illness. The growth of technically complex diagnostic tools for contamination is another major propeller for the industry.

An outbreak of flu can also be a global issue. As a result, huge amounts of R&D initiatives are launched for detection and drug improvement. In the majority of cases, the main research focus is the production of tests that can give fast and precise results on flu viruses in the quickest amount of time.

In 2019, the Centres for Collaborative Research on Influenza Vaccine Innovations (CIVICS) program, which is administered by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), was established to finance a variety of research initiatives pertaining to influenza epidemiology. Generously by NIAID (NIMB), the budgeted amount was USD 51 million emerged as the result of the first year of CIVIC's (Center for Integration of Veterans into the Civic Community) launch.

Key Insights

In 2023, the Test kits and reagent category held a leading market share of 60%.

This is due to the fact that these ailments are currently more common and with a notable rising attention towards early diagnosis.

However, points like ease of access without the necessity of writing a prescription (readily available on the market through pharmacies, retail stores, and online channels), ease of use, quick effect towards weight loss results, and affordable costs result in the growth of this category.

Together with the practical over-the-kit tests, the flu spread can be stopped because the isolated testing can be done without any contact with a suspected carrier.

Point-of-care testing allows people to economize by sending for professionals who are called in to conduct the tests. They also enjoy the tests being easy to conduct by themselves.

In 2023, the traditional category led the industry with a share of 40%.

The category is projected to experience a higher CAGR over the projection period.

Rapid influenza diagnostic tests within this category generated the highest revenue because of their simple use and fast results.

Augmented need for patient handling and surveillance testing for contagions in clinical settings.

Numerous RIDTs are accepted for use at houses and offices, with sanction from CLIA for usage in point-of-care services.

In 2023, the North American region held 65% of the revenue share, because of wide government surveillance, the existence of top companies, and technical improvements.

Well-recognized healthcare infrastructure and helpful reimbursement guidelines propel industry development.

European Union is projected to have a substantial share because of its aging populace, with more than one-fifth being 65 years or more in 2021.

Surging the possibility of flu in elders has led to WHO's recommendation of vaccinating senior people.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by product
    • 1.4.2. Market size breakdown, by test type
    • 1.4.3. Market size breakdown, by end user
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Product (2017-2030)
  • 6.3. Market Revenue, by Test Type (2017-2030)
    • 6.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 6.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 6.4. Market Revenue, by End User (2017-2030)
  • 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Product (2017-2030)
  • 7.3. Market Revenue, by Test Type (2017-2030)
    • 7.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 7.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 7.4. Market Revenue, by End User (2017-2030)
  • 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Product (2017-2030)
  • 8.3. Market Revenue, by Test Type (2017-2030)
    • 8.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 8.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 8.4. Market Revenue, by End User (2017-2030)
  • 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Product (2017-2030)
  • 9.3. Market Revenue, by Test Type (2017-2030)
    • 9.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 9.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 9.4. Market Revenue, by End User (2017-2030)
  • 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Product (2017-2030)
  • 10.3. Market Revenue, by Test Type (2017-2030)
    • 10.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 10.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 10.4. Market Revenue, by End User (2017-2030)
  • 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Product (2017-2030)
  • 11.3. Market Revenue, by Test Type (2017-2030)
    • 11.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 11.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 11.4. Market Revenue, by End User (2017-2030)
  • 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Product (2017-2030)
  • 12.3. Market Revenue, by Test Type (2017-2030)
    • 12.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 12.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Product (2017-2030)
  • 13.3. Market Revenue, by Test Type (2017-2030)
    • 13.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 13.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Product (2017-2030)
  • 14.3. Market Revenue, by Test Type (2017-2030)
    • 14.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 14.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Product (2017-2030)
  • 15.3. Market Revenue, by Test Type (2017-2030)
    • 15.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 15.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Product (2017-2030)
  • 16.3. Market Revenue, by Test Type (2017-2030)
    • 16.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 16.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Product (2017-2030)
  • 17.3. Market Revenue, by Test Type (2017-2030)
    • 17.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 17.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Product (2017-2030)
  • 18.3. Market Revenue, by Test Type (2017-2030)
    • 18.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 18.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Product (2017-2030)
  • 19.3. Market Revenue, by Test Type (2017-2030)
    • 19.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 19.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Product (2017-2030)
  • 20.3. Market Revenue, by Test Type (2017-2030)
    • 20.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 20.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Product (2017-2030)
  • 21.3. Market Revenue, by Test Type (2017-2030)
    • 21.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 21.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Product (2017-2030)
  • 22.3. Market Revenue, by Test Type (2017-2030)
    • 22.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 22.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Product (2017-2030)
  • 23.3. Market Revenue, by Test Type (2017-2030)
    • 23.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 23.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Product (2017-2030)
  • 24.3. Market Revenue, by Test Type (2017-2030)
    • 24.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 24.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Product (2017-2030)
  • 25.3. Market Revenue, by Test Type (2017-2030)
    • 25.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 25.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Product (2017-2030)
  • 26.3. Market Revenue, by Test Type (2017-2030)
    • 26.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 26.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Product (2017-2030)
  • 27.3. Market Revenue, by Test Type (2017-2030)
    • 27.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 27.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Product (2017-2030)
  • 28.3. Market Revenue, by Test Type (2017-2030)
    • 28.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 28.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. 3M Company
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. Abbott Laboratories Inc.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Becton, Dickinson and Company
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Meridian Bioscience Inc.
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. QuidelOrtho Corporation
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. F. Hoffmann-La Roche Ltd.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. SA Scientific Ltd.
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. Sekisui Diagnostics LLC
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Thermo Fisher Scientific Inc.
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary
  • 30.10. Hologic Inc.
    • 30.10.1. Business overview
    • 30.10.2. Product and service offerings
    • 30.10.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports